Later, the CANTOS (n = 10,061) international randomized trial with a follow-up median of 3.7 years showed that despite optimal drug treatment, in the same group, anti-cytokine therapy can reduce major cardiovascular events in people with stable coronary heart disease and highly sensitive CRP >2 mg/L. This evidence concerns the gene CRP and coronary artery disorder.